Physician profile
Roberta Crawford
NPI 1871689349
$5,228.98
in general payments reported to CMS, 2019-2025
21 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $256 · 2021: $562 · 2022: $670 · 2023: $1,066 · 2024: $766 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.78 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $651.38 | 2019-2025 | Rocklatan, Clareon, Argos |
| Allergan, INC. | $570.98 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $343.49 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Oyster Point Pharma, INC. | $298.96 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $284.50 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $238.57 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $198.76 | 2019-2021 | |
| Astellas Pharma US INC | $192.52 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $185.06 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $181.05 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $163.97 | 2019-2025 | Cequa |
| Thea Pharma INC. | $132.55 | 2022-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $116.69 | 2023-2025 | Acthar |
| Biotissue Holdings INC. | $86.57 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $86.55 | 2023-2024 | Iheezo |
| Eyevance Pharmaceuticals LLC | $77.38 | 2021-2022 | |
| Ocular Therapeutix, INC. | $76.17 | 2021-2025 | Dextenza |
| Rxsight INC | $14.95 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
| Shire North American Group INC | $13.61 | 2019 | |
| Sight Sciences, INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.